S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic α-Secretase Activity Acts via Selective Promotion of ADAM-10
Figure 2
Selective elevation of S100A7 protein in the CSF of AD cases relative to neurologically normal control cases or PD cases.
Monoclonal anti-human S100A7 antibody was used in a single antibody ELISA assay to quantify the content of S100A7 immunoreactivity in the CSF of non-medicated AD (n = 49), Parkinson's disease (n = 21), and neurological normal control (n = 10) cases. In this study, microtiter wells were coated with the antigen (0.5 µl CSF diluted 200-fold), dissolved in 100 µl of Buffer 42 (30 mM NaHCO3, 70 mM Na2CO3, 0.05% NaN3, pH 9.6), and incubated at 4°C overnight. Data are shown as a scatter plot. *P<0.05 vs. neurological controls or PD cases by one-way ANOVA.